For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Moderna Therapeutics, Inc.

USPTO Granted Patents = 34

EPO Patents = 5

Trademarks = 9

Forward Citations = 3,678

Loading Chart...

Loading Chart...

21 inventors (with patents filed for the assignee):

Antonin De Fougerolles (29 out of 91 patents)

Tirtha Chakraborty (20 out of 43 patents)

Jason P Schrum (13 out of 29 patents)

4. Stephane Bancel (9 out of 31 patents)

5. Sayda Mahgoub Elbashir (8 out of 56 patents)

6. Kristy M Wood (8 out of 18 patents)

7. Ron Weiss (5 out of 37 patents)

8. Kenechi Ejebe (5 out of 19 patents)

9. Jeff Lynn Ellsworth (4 out of 25 patents)

10. Atanu Roy (4 out of 22 patents)

11. Susan Whoriskey (4 out of 15 patents)

12. Paul Hatala (4 out of 16 patents)

13. Noubar Boghos Afeyan (4 out of 77 patents)

14. Matthias John (3 out of 13 patents)

15. Justin Guild (3 out of 22 patents)

34 patents: Sort by Forward Citations

1. 9675668 - Modified polynucleotides encoding hepatitis A virus cellular receptor 2 (2017-06-13),

2. 9464124 - Engineered nucleic acids and methods of use thereof (2016-10-11),

3. 9447164 - Engineered nucleic acids and methods of use thereof (2016-09-20),

4. 9428535 - Modified nucleosides, nucleotides, and nucleic acids, and uses thereof (2016-08-30),

5. 9334328 - Modified nucleosides, nucleotides, and nucleic acids, and uses thereof (2016-05-10),

6. 9303079 - Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins (2016-04-05),

7. 9301993 - Modified polynucleotides encoding apoptosis inducing factor 1 (2016-04-05),

8. 9295689 - Formulation and delivery of PLGA microspheres (2016-03-29),

9. 9283287 - Modified polynucleotides for the production of nuclear proteins (2016-03-15),

10. 9271996 - Formulation and delivery of PLGA microspheres (2016-03-01),

11. 9255129 - Modified polynucleotides encoding SIAH E3 ubiquitin protein ligase 1 (2016-02-09),

12. 9254311 - Modified polynucleotides for the production of proteins (2016-02-09),

13. 9233141 - Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders (2016-01-12),

14. 9221891 - In vivo production of proteins (2015-12-29),

15. 9220792 - Modified polynucleotides encoding aquaporin-5 (2015-12-29),

Moderna Therapeutics, Inc. is a biotechnology company focused on developing mRNA-based medicines. The company leverages its proprietary mRNA technology platform to create a new class of transformative medicines. Moderna's mRNA medicines have the potential to address a wide range of diseases, including infectious diseases, rare diseases, cardiovascular conditions, and more. With a mission to deliver on the promise of mRNA science, Moderna is dedicated to advancing the field of mRNA therapeutics through ongoing research and development.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

34 Patents

#66 in Cambridge, MA

#571 in Massachusetts

#9,678 in US

#19,056 in the World

Cambridge, MA, United States of America

Moderna Therapeutics, Inc.

Forward Citations = 3,678

21 inventors:

Antonin De Fougerolles (29 out of 91 patents)

Tirtha Chakraborty (20 out of 43 patents)

Jason P Schrum (13 out of 29 patents)

4. Stephane Bancel (9 out of 31 patents)

5. Sayda Mahgoub Elbashir (8 out of 56 patents)

Please report any incorrect information to support@idiyas.com

Loading…